References
[1] Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2016 Jul 14;13(8):501.
[2] Heijman J, Algalarrondo V, Voigt N, et al. The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis. Cardiovasc Res. 2016;109(4):467-479.
[3] Zahid S, Cochet H, Boyle PM, et al. Patient-derived models link re-entrant driver localization in atrial fibrillation to fibrosis spatial pattern. Cardiovasc Res. 2016;110(3):443-454.
[4] Cui N, Hu M, Khalil RA. Biochemical and Biological Attributes of Matrix Metalloproteinases. Prog Mol Biol Transl Sci. 2017;147:1-73.
[5] Spinale FG, Villarreal F. Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol. 2014;90(1):7-15.
[6] Li G, Yang J, Zhang D, Wang X, Han J, Guo X. Research Progress of Myocardial Fibrosis and Atrial Fibrillation. Front Cardiovasc Med. 2022;9:889706. Published 2022 Jul 25.
[7] Raffetto JD, Ross RL, Khalil RA. Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K+ channels: relevance to varicose vein formation. J Vasc Surg. 2007;45(2):373-380.
[8] Gao L, Zheng YJ, Gu SS, et al. Degradation of cardiac myosin light chain kinase by matrix metalloproteinase-2 contributes to myocardial contractile dysfunction during ischemia/reperfusion. J Mol Cell Cardiol. 2014;77:102-112.
[9] Pellman J, Sheikh F. Atrial fibrillation: mechanisms, therapeutics, and future directions. Compr Physiol. 2015;5(2):649-665.
[10] Wachtell, K., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Journal of the American College of Cardiology, 2005. 45(5): p. 712-719.
[11] Jia, M., et al. Role of matrix metalloproteinase‑7 and apoptosis‑associated gene expression levels in the pathogenesis of atrial fibrosis in a Beagle dog model. Mol Med Rep, 2017.16(5): p.6967-6973.
[12] Polyakova V, Miyagawa S, Szalay Z, Risteli J, Kostin S. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med. 2008; 12(1):189-208.
[13] Zhan, G., et al. Potential roles of circulating matrix metalloproteinase-28 (MMP-28) in patients with atrial fibrillation. Life Sciences, 2018. 204: p.15-19.
[14] Moe, G. W., et al. Matrix Metalloproteinase Inhibition Attenuates Atrial Remodeling and Vulnerability to Atrial Fibrillation in a Canine Model of Heart Failure. Journal of Cardiac Failure, 2008. 14(9):p.768-776.
[15] Gai X, Zhang Z, Liang Y, et al. MMP-2 and TIMP-2 gene polymorphisms and susceptibility to atrial fibrillation in Chinese Han patients with hypertensive heart disease. Clin Chim Acta. 2010; 411(9-10):719-724.
[16] Foronjy, R.F., et al. Transgenic Expression of Matrix Metalloproteinase-1 Inhibits Myocardial Fibrosis and Prevents the Tran-sition to Heart Failure in a Pressure Overload Mouse Model. Hypertension Research, 2008. 31(4):p.725-735.
[17] Gould PA, Yii M, McLean C, et al. Evidence for increased atrial sympathetic innervation in persistent human atrial fibrillation. Pacing Clin Electrophysiol. 2006; 29(8):821-829.
[18] Tan AY, Zhou S, Ogawa M, et al. Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. Circulation. 2008; 118(9):916-925.
[19] Kneller J, Zou R, Vigmond EJ, Wang Z, Leon LJ, Nattel S. Cholinergic atrial fibrillation in a computer model of a two-dimensional sheet of canine atrial cells with realistic ionic properties. Circ Res. 2002;90(9):E73-E87.
[20] Lee JK, Shin JH, Suh J, Choi IS, Ryu KS, Gwag BJ. Tissue inhibitor of metalloproteinases-3 (TIMP-3) expression is increased during serum deprivation-induced neuronal apoptosis in vitro and in the G93A mouse model of amyotrophic lateral sclerosis: a potential modulator of Fas-mediated apoptosis. Neurobiol Dis. 2008;30(2):174-185.
[21] Łukaszewicz-Zając M, Mroczko B, Słowik A. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS). J Neural Transm (Vienna). 2014; 121(11):1387-1397.
[22] Waldron, Ashley L et al. “Oxidative stress-dependent MMP-13 activity underlies glucose neurotoxicity.” Journal of diabetes and its complications, vol. 32, 3 (2018): 249-257.
[23] Staff, Nathan P, et al. “Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems.” Experimental neurology, vol. 324 (2020): 113121.
[24] Ferroni, Patrizia et al. “Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation.” Journal of investigative medicine: the official publication of the American Federation for Clinical Research vol. 51, 5 (2003): 295-300.
[25] Fiorentino, Loredana, et al. “Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay.” EMBO molecular medicine, vol. 5, 3 (2013): 441-55.
[26] Elia C, et al. “Alcohol modulation of cardiac matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs favors collagen accumulation.” Alcoholism, clinical and experimental research, vol. 38, 2 (2014): 448-56. doi:10.1111/acer.12239.
[27] Uemura, S, et al. “Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress.” Circulation research, vol. 88, 12 (2001): 1291-8.
[28] Papathanasiou, Konstantinos A, et al. “Molecular Insights in Atrial Fibrillation Pathogenesis and Therapeutics: A Narrative Review.” Diagnostics (Basel, Switzerland) vol. 11, 9 1584. 31 Aug. 2021.
[29] Polyakova, V., et al. Atrial extracellular matrix remodelling in patients with atrial fibrillation. Journal of cellular and molecular medicine, 2008. 12(1): p. 189-208.
[30] Kornej, J., et al. Addition of TGF-β1 to existing clinical risk scores does not improve prediction for arrhythmia recurrences after catheter ablation of atrial fibrillation. International Journal of Cardiology, 2016. 221: p. 52-54.